Document Type
Article
Publication Date
2-1-2012
Abstract
Individualized patient management is rapidly evolving, driven by the emergence of insights in discovery, development, regulatory, and comparative effectiveness sciences.1-4 The pace of discovery is accelerating, enabled by platforms, including “omics”, stem cell biology, network medicine, and medical and biological informatics that provide unanticipated insights into pathophysiology.2, 4-6 The integration of these paradigms has established a model for identifying the mechanistic underpinnings of disease, offering novel opportunities to individualize diagnostics that shape how modern therapies are deployed, including markers of disease prognosis, clinical predictors of therapeutic responses, and molecular determinants that optimize clinical management.7-10 Importantly, deconvolution of physiological circuits is producing a new vanguard of molecular therapies that target corrupted pathways at the center of disease pathogenesis, individualizing patient care algorithms that optimize benefits and minimize adverse effects.
Recommended Citation
Waldman, Scott A. and Terzic, Andre, "The value proposition of molecular medicine." (2012). Department of Pharmacology and Experimental Therapeutics Faculty Papers. Paper 33.
https://jdc.jefferson.edu/petfp/33
PubMed ID
22376267
Comments
This article has been peer reviewed. It is the authors' final version prior to publication in Clinical and Translational Science
Volume 5, Issue 1, February 2012, Pages 108-110.
The published version is available at DOI: 10.1111/j.1752-8062.2011.00386.x. Copyright © John Wiley & Sons, Inc.